Pentosidine and increased fracture risk in older adults with type 2 diabetes

Ann V. Schwartz, Patrick Garnero, Teresa A. Hillier, Deborah E. Sellmeyer, Elsa S. Strotmeyer, Kenneth R. Feingold, Helaine E. Resnick, Frances Tylavsky, Dennis M. Black, Steven R. Cummings, Tamara B. Harris, Douglas C. Bauer

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Context: Type 2 diabetes is associated with higher fracture risk at a given bone mineral density. Advanced glycation endproducts (AGEs) accumulate in bone collagen with age and diabetes and may weaken bone. Objective: The aim was to determine whether urine pentosidine, an AGE, was associated with fractures in older adults with and without diabetes. Design: We performed an observational cohort study. Setting: We used data from the Health, Aging and Body Composition prospective study of white and black, well-functioning men and women ages 70-79 yr. Participants: Participants with (n = 501) and without (n = 427) diabetes were matched on gender, race, and study site. Predictor: Urine pentosidine was assayed from frozen stored baseline specimens. Main Outcome Measures: Incident clinical fractures and baseline vertebral fractures were measured. Results: Despite higher bone mineral density, clinical fracture incidence (14.8 vs. 12.6%) and vertebral fracture prevalence (2.3 vs. 2.9%) were not lower in those with diabetes (P > 0.05). In multivariable models, pentosidine was associated with increased clinical fracture incidence in those with diabetes [relative hazard, 1.42; 95% confidence interval (CI), 1.10, 1.83, for 1 SD increase in log pentosidine] but not in those without diabetes (relative hazard, 1.08; 95% CI, 0.79, 1.49; P value for interaction = 0.030). In those with diabetes, pentosidine was associated with increased vertebral fracture prevalence (adjusted odds ratio, 5.93; 95% CI, 2.08, 16.94, for 1 SD increase in log pentosidine) but not in those without diabetes (adjusted odds ratio, 0.74; 95% CI, 0.30, 1.83; P value for interaction = 0.005). Conclusions: Higher pentosidine levels are a risk factor for fracture in older adults with diabetes and may account in part for reduced bone strength in type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)2380-2386
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number7
DOIs
StatePublished - Jan 1 2009

Fingerprint

Medical problems
Type 2 Diabetes Mellitus
Confidence Intervals
Bone
Bone and Bones
Bone Density
Odds Ratio
Urine
Minerals
Incidence
Hazards
pentosidine
Body Composition
Observational Studies
Cohort Studies
Collagen
Outcome Assessment (Health Care)
Prospective Studies
Health
Aging of materials

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Schwartz, A. V., Garnero, P., Hillier, T. A., Sellmeyer, D. E., Strotmeyer, E. S., Feingold, K. R., ... Bauer, D. C. (2009). Pentosidine and increased fracture risk in older adults with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 94(7), 2380-2386. https://doi.org/10.1210/jc.2008-2498

Pentosidine and increased fracture risk in older adults with type 2 diabetes. / Schwartz, Ann V.; Garnero, Patrick; Hillier, Teresa A.; Sellmeyer, Deborah E.; Strotmeyer, Elsa S.; Feingold, Kenneth R.; Resnick, Helaine E.; Tylavsky, Frances; Black, Dennis M.; Cummings, Steven R.; Harris, Tamara B.; Bauer, Douglas C.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 7, 01.01.2009, p. 2380-2386.

Research output: Contribution to journalArticle

Schwartz, AV, Garnero, P, Hillier, TA, Sellmeyer, DE, Strotmeyer, ES, Feingold, KR, Resnick, HE, Tylavsky, F, Black, DM, Cummings, SR, Harris, TB & Bauer, DC 2009, 'Pentosidine and increased fracture risk in older adults with type 2 diabetes', Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2380-2386. https://doi.org/10.1210/jc.2008-2498
Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2009 Jan 1;94(7):2380-2386. https://doi.org/10.1210/jc.2008-2498
Schwartz, Ann V. ; Garnero, Patrick ; Hillier, Teresa A. ; Sellmeyer, Deborah E. ; Strotmeyer, Elsa S. ; Feingold, Kenneth R. ; Resnick, Helaine E. ; Tylavsky, Frances ; Black, Dennis M. ; Cummings, Steven R. ; Harris, Tamara B. ; Bauer, Douglas C. / Pentosidine and increased fracture risk in older adults with type 2 diabetes. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 7. pp. 2380-2386.
@article{b66489372d7a4d08b4e41e93518c1fc6,
title = "Pentosidine and increased fracture risk in older adults with type 2 diabetes",
abstract = "Context: Type 2 diabetes is associated with higher fracture risk at a given bone mineral density. Advanced glycation endproducts (AGEs) accumulate in bone collagen with age and diabetes and may weaken bone. Objective: The aim was to determine whether urine pentosidine, an AGE, was associated with fractures in older adults with and without diabetes. Design: We performed an observational cohort study. Setting: We used data from the Health, Aging and Body Composition prospective study of white and black, well-functioning men and women ages 70-79 yr. Participants: Participants with (n = 501) and without (n = 427) diabetes were matched on gender, race, and study site. Predictor: Urine pentosidine was assayed from frozen stored baseline specimens. Main Outcome Measures: Incident clinical fractures and baseline vertebral fractures were measured. Results: Despite higher bone mineral density, clinical fracture incidence (14.8 vs. 12.6{\%}) and vertebral fracture prevalence (2.3 vs. 2.9{\%}) were not lower in those with diabetes (P > 0.05). In multivariable models, pentosidine was associated with increased clinical fracture incidence in those with diabetes [relative hazard, 1.42; 95{\%} confidence interval (CI), 1.10, 1.83, for 1 SD increase in log pentosidine] but not in those without diabetes (relative hazard, 1.08; 95{\%} CI, 0.79, 1.49; P value for interaction = 0.030). In those with diabetes, pentosidine was associated with increased vertebral fracture prevalence (adjusted odds ratio, 5.93; 95{\%} CI, 2.08, 16.94, for 1 SD increase in log pentosidine) but not in those without diabetes (adjusted odds ratio, 0.74; 95{\%} CI, 0.30, 1.83; P value for interaction = 0.005). Conclusions: Higher pentosidine levels are a risk factor for fracture in older adults with diabetes and may account in part for reduced bone strength in type 2 diabetes.",
author = "Schwartz, {Ann V.} and Patrick Garnero and Hillier, {Teresa A.} and Sellmeyer, {Deborah E.} and Strotmeyer, {Elsa S.} and Feingold, {Kenneth R.} and Resnick, {Helaine E.} and Frances Tylavsky and Black, {Dennis M.} and Cummings, {Steven R.} and Harris, {Tamara B.} and Bauer, {Douglas C.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1210/jc.2008-2498",
language = "English (US)",
volume = "94",
pages = "2380--2386",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Pentosidine and increased fracture risk in older adults with type 2 diabetes

AU - Schwartz, Ann V.

AU - Garnero, Patrick

AU - Hillier, Teresa A.

AU - Sellmeyer, Deborah E.

AU - Strotmeyer, Elsa S.

AU - Feingold, Kenneth R.

AU - Resnick, Helaine E.

AU - Tylavsky, Frances

AU - Black, Dennis M.

AU - Cummings, Steven R.

AU - Harris, Tamara B.

AU - Bauer, Douglas C.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Context: Type 2 diabetes is associated with higher fracture risk at a given bone mineral density. Advanced glycation endproducts (AGEs) accumulate in bone collagen with age and diabetes and may weaken bone. Objective: The aim was to determine whether urine pentosidine, an AGE, was associated with fractures in older adults with and without diabetes. Design: We performed an observational cohort study. Setting: We used data from the Health, Aging and Body Composition prospective study of white and black, well-functioning men and women ages 70-79 yr. Participants: Participants with (n = 501) and without (n = 427) diabetes were matched on gender, race, and study site. Predictor: Urine pentosidine was assayed from frozen stored baseline specimens. Main Outcome Measures: Incident clinical fractures and baseline vertebral fractures were measured. Results: Despite higher bone mineral density, clinical fracture incidence (14.8 vs. 12.6%) and vertebral fracture prevalence (2.3 vs. 2.9%) were not lower in those with diabetes (P > 0.05). In multivariable models, pentosidine was associated with increased clinical fracture incidence in those with diabetes [relative hazard, 1.42; 95% confidence interval (CI), 1.10, 1.83, for 1 SD increase in log pentosidine] but not in those without diabetes (relative hazard, 1.08; 95% CI, 0.79, 1.49; P value for interaction = 0.030). In those with diabetes, pentosidine was associated with increased vertebral fracture prevalence (adjusted odds ratio, 5.93; 95% CI, 2.08, 16.94, for 1 SD increase in log pentosidine) but not in those without diabetes (adjusted odds ratio, 0.74; 95% CI, 0.30, 1.83; P value for interaction = 0.005). Conclusions: Higher pentosidine levels are a risk factor for fracture in older adults with diabetes and may account in part for reduced bone strength in type 2 diabetes.

AB - Context: Type 2 diabetes is associated with higher fracture risk at a given bone mineral density. Advanced glycation endproducts (AGEs) accumulate in bone collagen with age and diabetes and may weaken bone. Objective: The aim was to determine whether urine pentosidine, an AGE, was associated with fractures in older adults with and without diabetes. Design: We performed an observational cohort study. Setting: We used data from the Health, Aging and Body Composition prospective study of white and black, well-functioning men and women ages 70-79 yr. Participants: Participants with (n = 501) and without (n = 427) diabetes were matched on gender, race, and study site. Predictor: Urine pentosidine was assayed from frozen stored baseline specimens. Main Outcome Measures: Incident clinical fractures and baseline vertebral fractures were measured. Results: Despite higher bone mineral density, clinical fracture incidence (14.8 vs. 12.6%) and vertebral fracture prevalence (2.3 vs. 2.9%) were not lower in those with diabetes (P > 0.05). In multivariable models, pentosidine was associated with increased clinical fracture incidence in those with diabetes [relative hazard, 1.42; 95% confidence interval (CI), 1.10, 1.83, for 1 SD increase in log pentosidine] but not in those without diabetes (relative hazard, 1.08; 95% CI, 0.79, 1.49; P value for interaction = 0.030). In those with diabetes, pentosidine was associated with increased vertebral fracture prevalence (adjusted odds ratio, 5.93; 95% CI, 2.08, 16.94, for 1 SD increase in log pentosidine) but not in those without diabetes (adjusted odds ratio, 0.74; 95% CI, 0.30, 1.83; P value for interaction = 0.005). Conclusions: Higher pentosidine levels are a risk factor for fracture in older adults with diabetes and may account in part for reduced bone strength in type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=67650263891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650263891&partnerID=8YFLogxK

U2 - 10.1210/jc.2008-2498

DO - 10.1210/jc.2008-2498

M3 - Article

VL - 94

SP - 2380

EP - 2386

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -